• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Amikacin prevents ventilator-associated pneumonia in mechanically ventilated patients

byKiera Liblik
January 5, 2024
in Emergency, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, rates of ventilator-associated pneumonia (VAP) were lower in ventilated patients using amikacin as compared to a placebo. 

2. This difference was maintained over a 28-day follow-up period in the amikacin group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: VAP emerges 48 hours or more post-mechanical ventilation via an endotracheal tube or tracheostomy, contributing to escalated antimicrobial usage, resistance, prolonged intensive care unit (ICU) stays, and heightened mortality. The peak incidence surfaces after seven days of ventilation, offering a therapeutic window for mitigating VAP occurrence. A meta-analysis of nine trials with modest sample sizes demonstrated efficacy in VAP prevention. The Inhaled Amikacin vs. Placebo to Prevent VAP (AMIKINHAL) trial scrutinized the prophylactic potential of inhaled amikacin in reducing VAP incidence among critically ill adults ventilated for at least 72 hours. The multicenter, double-blind, randomized trial demonstrated a significant reduction in VAP occurrence in the amikacin group compared to the placebo group over a 28-day follow-up. Moreover, infection-related ventilator-associated complications were substantially lower in the amikacin group. As a limitation, this study was underpowered to assess mortality or duration of stay in the ICU. Overall, the trial posits that a subsequent three-day course of inhaled amikacin may effectively alleviate the burden of VAP in such patients.

Click here to read the study in NEJM

In-Depth [randomized controlled trial]: The study enrolled 850 participants from 19 ICUs in France, with 417 in the amikacin group after three patients withdrew consent and 430 in the placebo group. Patients were randomly assigned to receive either nebulized amikacin or nebulized sodium chloride, with blinding of treating physicians and participants. At randomization, 78% of patients were receiving systemic antibiotics. In the amikacin group, 337 patients (81%) completed all three scheduled nebulizations, while in the sodium chloride group, 335 patients (83%) completed all three scheduled nebulizations. The primary outcome was the development of VAP post-nebulization, with key secondary outcomes including length of stay, deaths, median days on mechanical ventilation, ventilator-associated events, and antibiotic days. At 28 days, ventilator-associated pneumonia had manifested in 62 patients (15%) in the amikacin group and 95 patients (22%) in the placebo group (difference in restricted mean survival time to ventilator-associated pneumonia, 1.5 days; 95% confidence interval [CI], 0.6 to 2.5; p=0.004). Furthermore, an infection-related ventilator-associated complication occurred in 74 patients (18%) in the amikacin group and 111 patients (26%) in the placebo group (hazard ratio, 0.66; 95% CI, 0.50 to 0.89). Trial-related serious adverse effects were observed in 7 patients (1.7%) in the amikacin group and four patients (0.9%) in the placebo group. This investigator-initiated trial provides invaluable insights into the potential preventive use of inhaled antibiotics in critically ill patients.

RELATED REPORTS

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

Frailty scores alone may be poor predictors of intensive care admission or hospital stay duration

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Amikacincritical careemergencyICUinfectious diseasepneumoniapulmonologyrespirologyventilator associated pneumonia
Previous Post

Wellness Check: Sleep

Next Post

#VisualAbstract: Rituximab maintenance therapy following autologous stem cell transplant increased survival in young patients with mantle-cell lymphoma

RelatedReports

Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

June 19, 2025
Chronic Disease

Frailty scores alone may be poor predictors of intensive care admission or hospital stay duration

June 16, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Infectious Disease

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

June 9, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 9, 2025

June 9, 2025
Next Post
#VisualAbstract: Rituximab maintenance therapy following autologous stem cell transplant increased survival in young patients with mantle-cell lymphoma

#VisualAbstract: Rituximab maintenance therapy following autologous stem cell transplant increased survival in young patients with mantle-cell lymphoma

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

Percutaneous coronary intervention associated with decreased stable angina symptoms

Women electing abortion more likely to be victims of domestic violence

Discontinuing oxytocin during active labour has no significant impact on neonatal morbidity

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.